EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
Public ClinicalTrials.gov record NCT03497689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil) Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin® (treprostinil) Injection in subjects with pulmonary arterial hypertension (PAH).
Study identification
- NCT ID
- NCT03497689
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 30, 2019
- Primary completion
- May 10, 2022
- Completion
- May 10, 2022
- Last update posted
- Aug 6, 2023
2019 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco - Fresno | Fresno | California | 93701 | — |
| Harbor-UCLA Medical Center | Torrance | California | 90502 | — |
| Florida Hospital | Orlando | Florida | 32803 | — |
| Piedmont Healthcare Pulmonary and Critical Care Research | Austell | Georgia | 30106 | — |
| St. Vincent Medical Group | Indianapolis | Indiana | 46260 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| University of New Mexico Health Sciences Center | Albuquerque | New Mexico | 87131 | — |
| University of Cincinnati Health | Cincinnati | Ohio | 45267 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Integris Baptist Medical Center | Oklahoma City | Oklahoma | 73112 | — |
| UPMC Presbytarian Hospital | Pittsburgh | Pennsylvania | 15213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03497689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03497689 live on ClinicalTrials.gov.